Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Phathom Pharmaceuticals ( (PHAT) ) has provided an announcement.
On November 4, 2025, Phathom Pharmaceuticals announced the commencement of its Phase 2 pHalcon EoE-201 clinical trial, marking the first dosing of a patient with VOQUEZNA® (vonoprazan) tablets for eosinophilic esophagitis in adults. This two-part, randomized, double-blind, placebo-controlled study aims to enroll 80 adults with EoE and dysphagia, with results expected in 2027, potentially impacting Phathom’s market position in gastrointestinal treatments.
The most recent analyst rating on (PHAT) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
Spark’s Take on PHAT Stock
According to Spark, TipRanks’ AI Analyst, PHAT is a Neutral.
Phathom Pharmaceuticals has a mixed outlook. The strong performance in the latest earnings call, with significant revenue growth and cost reductions, is a positive factor. However, the company’s financial instability, negative valuation metrics, and reliance on external financing pose significant risks. Technical indicators show positive momentum, but the financial challenges weigh heavily on the overall score.
To see Spark’s full report on PHAT stock, click here.
More about Phathom Pharmaceuticals
Phathom Pharmaceuticals operates in the pharmaceutical industry, focusing on the development and commercialization of novel treatments for gastrointestinal diseases. The company’s primary product, VOQUEZNA® (vonoprazan), is targeted at addressing conditions such as eosinophilic esophagitis and other acid-related disorders.
Average Trading Volume: 1,209,861
Technical Sentiment Signal: Buy
Current Market Cap: $976.7M
For a thorough assessment of PHAT stock, go to TipRanks’ Stock Analysis page.